21 November 2024 in New England Journal of Medicine
Genomic sequencing technology allows for identification of reproductive couples with an increased chance, as compared with that in the general population, of having a child with an autosomal recessive or X-linked genetic condition. We investigated the feasibility, acceptability, and outcomes of a nationwide, couple-based genetic carrier screening program in Australia as part of the Mackenzie's Mission project. Health care providers offered screening to persons before pregnancy or early in pregnancy. The results obtained from testing at least 1281 genes were provided to the reproductive couples. We aimed to ascertain the psychosocial effects on participants, the acceptability of screening to all participants, and the reproductive choices of persons identified as having an increased chance of having a child with a condition for which we screened. Among 10,038 reproductive couples enrolled in the study, 9107 (90.7%) completed screening, and 175 (1.9%) were newly identified as having an increased chance of having a child with a genetic condition for which we screened. These conditions involved pathogenic variants in 90 different genes; 74.3% of the conditions were autosomal recessive. Three months after receiving the results, 76.6% of the couples with a newly identified increased chance had used or planned to use reproductive interventions to avoid having an affected child. Those newly identified as having an increased chance had greater anxiety than those with a low chance. The median level of decisional regret was low in all result groups, and 98.9% of participants perceived screening to be acceptable. Couple-based reproductive genetic carrier screening was largely acceptable to participants and was used to inform reproductive decision making. The delivery of screening to a diverse and geographically dispersed population was feasible. (Funded by the Medical Research Future Fund of the Australian government; ClinicalTrials.gov number, NCT04157595.).
17 February 2025 in npj Genomic Medicine
In pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child’s raw data and/or biospecimen. To satisfy such requests, the ZERO Childhood Cancer Program required a guidance document. Literature review led to Version(V)1; Delphi consultation with 21/54 invited experts (V2–4) and parent consultations (V5–6). A final V7 was approved for implementation: Policy (purpose; background; ethical considerations), Process (nine steps), and consent form. Issues addressed included: child’s best interests, clinical utility, non-maleficence, reciprocity between researchers and participants/parents; responsibility to genetic relatives; acknowledging potential value of subsequent analysis/interpretation but no obligation on treating clinicians to act on therapeutic recommendations arising; practical barriers to return; and supporting parental empowerment by facilitating meeting with a study genetic counselor, separate from their treating clinician, if preferred, to manage their request. This guide may be a model for other research groups and inform ethical guidelines.
24 March 2025 in npj Genomic Medicine
12 June 2024 in Research Square
KBKristine Barlow-Stewart
+22
Sharing raw genomic data with research participants is not universally mandated. Yet, in padiatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child’s raw data and/or biospecimen. To satisfy such requests with ethical, timely and appropriate responses, the ZERO Childhood Cancer Program required development of a Policy and Process document. Development occurred iteratively: V1 from the literature; V2-4 following a modified Delphi expert consultation over three Rounds; V5-6 following two rounds of consumer consultation; and a final ethically approved V7: Policy (purpose; background; ethical considerations), Process (nine steps), leaflet for those making a request and consent form. Twenty-one Delphi experts (71% pediatric oncologists/hematologists, clinical geneticists/genetic counsellors – most likely involved with requests) achieved consensus (> 80%) by Round 3. Issues addressed included broadening ethical considerations (autonomy/child’s best interests, beneficence/clinical utility, non-maleficence, reciprocity, responsibility to genetic relatives); no obligation on treating clinicians to act on therapeutic recommendations arising; limiting practical barriers to return by streamlining the process. Consumer consultations highlighted need for expected turnaround times, given no reportable or actionable findings may trigger requests; acknowledging potential great value of subsequent analysis/interpretation; and supporting parental empowerment by facilitating meeting with a study genetic counselor (or equivalent), separate from their treating clinician, if preferred, to manage their request. Informed by expert consensus and consumer views, this guide to fulfilling data sharing requests, in a spirit of reciprocity between researchers and participants/parents/guardians, may be a model for other research groups and inform ethical guidelines.